When the steroidal farnesoid X-receptor agonist obeticholic acid was recently evaluated in Cyp2c70 KO mice, short-term 4-weeks treatment did not improve the hepatic fibrosis or development of cholangiopathy, despite suppressing BA synthesis (60). This evidence concerns the gene NR1H4 and Hepatic fibrosis.